Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;102(5):1188-1190.
doi: 10.1016/j.kint.2022.07.022. Epub 2022 Aug 13.

A rapid decline in the anti-receptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab-cilgavimab administration

Ilies Benotmane  1 , Aurélie Velay  2 , Gabriela-Gautier Vargas  3 , Jérôme Olagne  3 , Noëlle Cognard  3 , Françoise Heibel  3 , Laura Braun-Parvez  3 , Jonas Martzloff  3 , Peggy Perrin  3 , Romain Pszczolinski  3 , Bruno Moulin  4 , Samira Fafi-Kremer  2 , Sophie Caillard  4
Affiliations

A rapid decline in the anti-receptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab-cilgavimab administration

Ilies Benotmane et al. Kidney Int. 2022 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti–receptor-binding domain IgG titer kinetics tested by ARCHITECT IgG II Quant test (Abbott). Results in arbitrary units/ml specific of this assay were converted into binding antibody units (BAUs)/ml adapted to the World Health Organization standard for SARS-CoV-2 Ig by multiplying them by the factor 0.142 (assay range, 1–11,360 BAUs/ml). Titers are represented from the day of tixagevimab–cilgavimab administration for patients previously treated with the casirivimab–imdevimab combination (n = 72; b) or not (n = 26; a). For 28 patients, data were missing around 1 month after antibody administration. The black lines represent the threshold below which no neutralizing activity against the Omicron BA.1 variant was detected in our previous study. The thick blue lines indicate the trend in antibody titer using smoothing splines. The kinetics of neutralization were investigated in a subgroup of 18 patients, and a significant decrease was observed between 1 month (M1) and 4 to 5 months (M4–M5) following tixagevimab–cilgavimab injection (c). ∗∗P = 0.007. IC50, 50% inhibitory concentration; Nab, neutralizing antibody.
Figure 2
Figure 2
Scattergram and regression line showing a significant positive correlation between anti–receptor-binding domain (RBD) IgG (Abbott Architect) and neutralizing antibody (Nab) titers (Spearman ρ = 0.49; P = 0.02). IC50, 50% inhibitory concentration.
See this image and copyright information in PMC

References

    1. Caillard S., Chavarot N., Francois H., et al. Is COVID-19 infection more severe in kidney transplant recipients? Am J Transplant. 2021;21:1295–1303. - PMC - PubMed
    1. Caillard S., Thaunat O., Benotmane I., et al. Antibody response to a fourth messenger RNA COVID-19 vaccine dose in kidney transplant recipients: a case series. Ann Intern Med. 2022;175:455–456. - PMC - PubMed
    1. Ducloux D., Courivaud C. REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme. Kidney Int. 2022;101:645–646. - PMC - PubMed
    1. Levin M.J., Ustianowski A., De Wit S., et al. Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386:2188–2200. - PMC - PubMed
    1. Benotmane I., Velay A., Gautier-Vargas G., et al. Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant. Kidney Int. 2022;102:442–444. - PMC - PubMed